← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aavogen, Inc.
Rockville, MD
$4,728,767
Total funding
5
Grants
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,728,767 · 5
By mechanism
R44$3,879,616 · 2
R43$849,151 · 3
Investigators at Aavogen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia$1,206,955
R44 · FY2017 · CA
Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis$973,558
R44 · FY2023 · AG
Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis$904,058
R44 · FY2022 · AG
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia$660,235
R44 · FY2018 · CA
Preclinical validation of AVGN7 for treating obesity and type 2 diabetes mellitus.$350,000
R43 · FY2025 · DK
Preclinical Validation of AVGN7 for Treating Duchenne Muscular Dystrophy$224,999
R43 · FY2019 · AR
Development of optimized adeno-associated viral capsids for muscle gene therapy$140,152
R43 · FY2023 · AR
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia$134,809
R44 · FY2021 · CA
Development of optimized adeno-associated viral capsids for muscle gene therapy$134,000
R43 · FY2024 · AR
AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia$1
R44 · FY2019 · CA